The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

The following is a summary of “Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration,” published in the March 2025 issue of British Journal ...

The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET. Company Participants. Douglas Onsi - President ...

Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ...

These advances have opened the door for targeted anti-VEGF therapy, leading to significant improvements in visual outcomes for a majority of patients. There is, however, a portion of the ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024.

Leap Therapeutics (LPTX) presented updated preliminary data from Part B of the DeFianCe study, a Phase 2, open-label, global study of ...